Evidence map›Paper›PMID 42611165›Full record

ArticleClinical journal of gastroenterology2026

Successful administration of glecaprevir/pibrentasvir via percutaneous endoscopic gastrostomy in a pediatric patient with chronic hepatitis C and spinal muscular atrophy receiving risdiplam.

Marta Carfagna, Annalisa Carciofi, Alessandra Palpacelli, Emanuela Andresciani, Angela Maria Felicita Garzone, Giovanni Pieroni, Daniele Campioni, Federica Zallocco

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Marta CarfagnaPediatric Infectious Disease Unit, Salesi Children Hospital, Azienda Ospedaliero Universitaria delle Marche, Via F. Corridoni 11, 60123, Ancona, Italy. marta.carfagna@ospedaliriuniti.marche.it.ORCID http://orcid.org/0009-0004-0981-7161
Annalisa CarciofiDepartment of Pediatrics, Polytechnic University of Marche, Ancona, Italy.
Alessandra PalpacelliPediatric Infectious Disease Unit, Salesi Children Hospital, Azienda Ospedaliero Universitaria delle Marche, Via F. Corridoni 11, 60123, Ancona, Italy.
Emanuela AndrescianiHospital Pharmacy, Salesi Children Hospital, Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy.
Angela Maria Felicita GarzoneHospital Pharmacy, Salesi Children Hospital, Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy.
Giovanni PieroniDepartment of Radiological Sciences, Salesi Children Hospital, Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy.
Daniele CampioniDepartment of Radiological Sciences, Salesi Children Hospital, Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy.
Federica ZalloccoPediatric Infectious Disease Unit, Salesi Children Hospital, Azienda Ospedaliero Universitaria delle Marche, Via F. Corridoni 11, 60123, Ancona, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glecaprevir/Pibrentasvir (GLE/PIB) is an interferon-free direct-acting antiviral (DAA) regimen indicated for the treatment of chronic hepatitis C virus (HCV) infection. However, data on the pharmacokinetics and stability of crushed or split tablets are lacking, complicating administration in patients with dysphagia requiring percutaneous endoscopic gastrostomy (PEG). Additionally, no published studies have evaluated the safety and efficacy of DAAs in combination with Risdiplam, the first oral therapy developed for spinal muscular atrophy (SMA). We report a case of a 14-year-old dysphagic patient with SMA, receiving Risdiplam, who was successfully treated with crushed GLE/PIB administrated via PEG. The patient achieved a sustained virologic response (SVR) 12 weeks after the end of therapy, without significant adverse effects, and no drug interactions were observed during the course of treatment.

Indexed as

Crushed tabletsGlecaprevir/pibrentasvirHepatitis C virusPercutaneous endoscopic gastrostomy tubeRisdiplam

Identifiers

PMID42611165

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.